about
The Butantan Institute: history and future perspectives.Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.Development of Streptococcus pneumoniae Vaccines Using Live VectorsCorrelation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies.Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.Conserved surface accessible nucleoside ABC transporter component SP0845 is essential for pneumococcal virulence and confers protection in vivo.Risk factors for death from invasive pneumococcal disease, Europe, 2010.C-Terminal Clostridium perfringens Enterotoxin-Mediated Antigen Delivery for Nasal Pneumococcal VaccineT(H)17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins.A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A.Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein ARationale and prospects for novel pneumococcal vaccines.A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).Age-dependent prevalence of nasopharyngeal carriage of streptococcus pneumoniae before conjugate vaccine introduction: a prediction model based on a meta-analysisAge-related immune response to pneumococcal polysaccharide vaccination: lessons for the clinic.Pneumococcal conjugate vaccine use in adults.Safety and tolerability of pneumococcal vaccines in children.Strategies to develop vaccines of pediatric interest.Pneumococcal lipoproteins involved in bacterial fitness, virulence, and immune evasion.First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial.Identification of proteins in Streptococcus pneumoniae by reverse vaccinology and genetic diversity of these proteins in clinical isolates.Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity.Distribution of Streptococcus pneumoniae serotypes in the northeast macro-region of São Paulo state/Brazil after the introduction of conjugate vaccine.Pneumococcal Predictive Proteins Selected by Microbial Genomic Approach Are Serotype Cross-Reactive and Bind to Host Extracellular Matrix Proteins.Serotype distribution and penicillin-non-susceptibility of Streptococcus pneumoniae causing invasive diseases in Kuwait: A 10-year study of impact of pneumococcal conjugate vaccines.Promises and pitfalls of live attenuated pneumococcal vaccines.Recombinant Escherichia coli cultivation in a pressurized airlift bioreactor: assessment of the influence of temperature on oxygen transfer and uptake rates.The immunological mechanisms that control pneumococcal carriage.Recent approaches in whole cell pneumococcal vaccine development: a review study.Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1.Intranasal Vaccination With Lipoproteins Confers Protection Against Pneumococcal ColonisationPuzzling Over the Pneumococcal Pangenome
P2860
Q33842834-45237004-0994-4DBA-8395-39345B845B65Q33899407-B610E768-D0AC-4D8B-B1E9-2DB91D27C384Q34316015-09EB19D2-40D2-41ED-9E94-1C6EA51B76D4Q34784957-3EE86212-1923-44AC-BF41-CD222FEEC4A3Q35021099-7C1B3140-744D-4DBC-ADAE-F43A651A87F4Q35092077-BBE53CF0-661E-4570-9151-5E1D9C0F2A2EQ35130282-38E28013-9F6B-4D33-AAA4-B2E7C8B5F88EQ35643907-E800C2B7-C0D0-4BB6-89EB-AAC95CAC24DDQ35902005-4A458431-2853-41F1-8742-BB48ACC94D26Q36409520-8DEBDD64-BFC3-4BB2-A5D7-2C670E9EF2E6Q37252358-8D9E481F-36EE-49C1-8FF4-2DFFC4EBA966Q37309218-3BEAD8E2-63DE-4C54-BC54-3723580FD12CQ37483596-E8C72886-224E-4DB3-9103-F73D1373B938Q37509931-4F2E02F1-E908-4E4F-9B69-A32B16E92001Q38255618-3F23D6FF-BAF0-4D4D-B4B1-5EE10113805EQ38664425-B8FAAFD9-05EF-4986-9067-CE1593298141Q38753554-854E6C08-9062-4B74-BAFA-6711118FA09BQ38819027-1F712A80-8360-4F72-B0FA-473828E991DDQ38923654-95DB7849-A845-48C7-BA46-93AF9E33E4D4Q38950882-E713617E-0B42-4939-A19A-E09506EDDC2EQ39089994-5A669908-DF80-4563-9391-3A287E06014AQ39164566-7A30066D-23B9-466F-ACD4-DEA2765447D7Q40079452-CFB47646-2324-42EB-8CCE-1996159674A8Q40328473-A1881C47-2C50-49E5-9F04-B8379C5B3CD5Q40643836-61F52BB1-09CF-4230-8F26-23AE5080241CQ41612508-DD2A18ED-931D-4445-B693-4DB273A12064Q47748402-087BB8CC-E076-46AF-9A31-4D6949D5034DQ48364114-26C20727-8C7E-407A-8E2D-D24F9C36D9B8Q50305151-3CE85B2F-9FC4-451C-B1B4-D2077FC9DA4AQ52365761-BCE5842C-E9E0-4E47-A4B3-7184CEE9757AQ58596157-C6241295-8B8D-4180-9B83-23E5652AA9B0Q58693896-1F849B1E-5833-4B07-9919-279FD906B2A3
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Serotype-independent pneumococcal vaccines.
@en
type
label
Serotype-independent pneumococcal vaccines.
@en
prefLabel
Serotype-independent pneumococcal vaccines.
@en
P2860
P1476
Serotype-independent pneumococcal vaccines
@en
P2093
Eneas Carvalho
Paulo Lee Ho
P2860
P2888
P304
P356
10.1007/S00018-012-1234-8
P577
2012-12-27T00:00:00Z